Aptose Biosciences (APTO) 6-K Current report (foreign)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE13a-16 OR15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2018

Commission File Number:001-32001

Aptose Biosciences Inc.

(Translation of registrant’s name into English)

5955 Airport Road, Suite 228

Mississauga, Ontario L4V 1R9

Canada

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F.

Form20-F  ☐            Form40-F  ☑

Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1)  ☐

Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7)  ☐

INCORPORATION BY REFERENCE

Exhibit 99.1 to this Report on Form6-K is hereby incorporated by reference as an Exhibit to the Registration Statement on FormF-10 of Aptose Biosciences Inc. (FileNo. 333-222909).

DOCUMENTS FILED AS PART OF THIS FORM6-K

See the Exhibit Index hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Aptose Biosciences Inc.
Date: March 28, 2018	By:	/s/ Gregory Chow

Name:	Gregory Chow
Title:	Senior Vice President and Chief Financial Officer

2

EXHIBIT INDEX

Exhibit	Description
99.1	Sales Agreement, dated March 27, 2018